Baird raised the firm’s price target on CVS Health (CVS) to $71 from $51 and keeps a Neutral rating on the shares. The firm sees minimal incremental buyers of stocks in the managed care and healthcare facilities group until the policy overhang clears. Baird does not not expect guidance raises as it believes companies will maintain 2025 “conservatism and cushion” given potential Part D and macro headwinds that may evolve later this year.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CVS:
- CVS Health Stock Soars: Strategic Moves and Market Boost
- CVS Health price target raised to $82 from $76 at Truist
- CVS Health price target raised to $76 from $70 at Mizuho
- Macro Headwind-Immune CVS Health Stock Set to Extend 50% YTD Rally
- 3 ‘Strong Buy’ Stocks to Consider as Tariffs Push S&P 500 (SPX) Toward Bear Market